Health

Primary care doctors warn as telehealth firms move into obesity drugs

Filed Jun 15, 2026 · 00:16

Event Jun 14, 2026

# Primary care doctors warn as telehealth firms move into obesity drugs

> Primary care doctors are raising concerns as telehealth companies expand into prescribing GLP-1 weight-loss drugs and offering lifestyle support, while employers press to contain the soaring cost of those medications.

**Filed:** 2026-06-15 00:16 UTC  
**Event:** Jun 14, 2026  
**Category:** Health  
**Source:** NPR (https://www.npr.org/2026/06/14/nx-s1-5805984/glp1-telehealth-weight-loss-drugs)

---


Primary care physicians are [raising alarms](https://www.npr.org/2026/06/14/nx-s1-5805984/glp1-telehealth-weight-loss-drugs) as telehealth companies move deeper into the booming market for GLP-1 weight-loss drugs, adding lifestyle and coaching services around the prescriptions, NPR reports. The worry is continuity of care: managing obesity drugs through a standalone telehealth channel can sideline the clinician who sees the rest of a patient's health picture.

Sitting behind the clinical debate is a cost fight. Employers, facing rapidly rising spending on GLP-1s, are pushing to rein in how widely the drugs are prescribed and reimbursed — which shapes who gets access and through which channel. The tension between expanding demand and payers' appetite to contain it is likely to define how these medications are delivered.

[Read the source →](https://www.npr.org/2026/06/14/nx-s1-5805984/glp1-telehealth-weight-loss-drugs)

Primary care physicians are raising alarms as telehealth companies move deeper into the booming market for GLP-1 weight-loss drugs, adding lifestyle and coaching services around the prescriptions, NPR reports. The worry is continuity of care: managing obesity drugs through a standalone telehealth channel can sideline the clinician who sees the rest of a patient’s health picture.

Sitting behind the clinical debate is a cost fight. Employers, facing rapidly rising spending on GLP-1s, are pushing to rein in how widely the drugs are prescribed and reimbursed — which shapes who gets access and through which channel. The tension between expanding demand and payers’ appetite to contain it is likely to define how these medications are delivered.

Read the source →